Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Implantica

52.30 SEK

-0.95 %

Less than 1K followers

IMP A SDB

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.95 %
+4.70 %
-11.80 %
+21.91 %
+52.03 %
+52.92 %
+24.97 %
-53.68 %
-45.84 %

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Read more
Market cap
61.88B SEK
Turnover
1.72M SEK
Revenue
22.25M
EBIT %
-1,312.89 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/2
2026

Annual report '25

All
Webcasts
Press releases
ShowingAll content types
Press release11/25/2025, 7:00 AM

Implantica: RefluxStop® utnämnt till "Bäst i sin klass" vid Japan Foregut Conference efter presentation av 5 års data och omfattande säkerhetskohort för 120 ledande kirurger

Implantica
Press release11/25/2025, 7:00 AM

Implantica: RefluxStop® "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons

Implantica
Press release11/11/2025, 7:00 AM

Implantica: RefluxStop® takes center stage at 2025 European Foregut Society meeting

Implantica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/11/2025, 7:00 AM

Implantica: RefluxStop® står i centrum vid European Foregut Society-mötet 2025

Implantica
Implantica, Webcast, Q3'25
Webcast10/31/2025, 2:00 PM

Implantica, Webcast, Q3'25

Implantica
Regulatory press release10/31/2025, 7:00 AM

Implantica publishes Interim Report January - September 2025 (Q3)

Implantica
Regulatory press release10/31/2025, 7:00 AM

Implantica publicerar delårsrapport januari - september 2025 (Q3)

Implantica
Press release10/27/2025, 8:30 AM

Implantica presents the third quarter 2025 on October 31 at 15:00 CET

Implantica
Press release10/27/2025, 8:30 AM

Implantica presenterar tredje kvartalet för 2025, den 31 oktober kl. 15:00 CET

Implantica
Press release10/13/2025, 8:30 AM

Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application

Implantica
Press release10/13/2025, 8:30 AM

Implantica avslutar FDA:s 100-dagarsmöte för RefluxStop® PMA-ansökan

Implantica
Press release10/6/2025, 6:00 AM

Implantica framgångsrikt slutför sin MDSAP-recertifieringsrevision

Implantica
Press release10/6/2025, 6:00 AM

Implantica Successfully Completes MDSAP Recertification Audit

Implantica
Press release9/25/2025, 6:00 AM

Implantica trappar upp för att fylla behandlingsgapet med RefluxStop® när primära implantat-konkurrenten lämnar Europa och Storbritannien

Implantica
Press release9/25/2025, 6:00 AM

Implantica steps up to close the treatment gap with RefluxStop® as main device competitor exits Europe and the UK

Implantica
Press release9/24/2025, 6:00 AM

Implantica meddelar att amerikanska FDA har återkopplat på den finala modulen i RefluxStops® PMA-ansökan, Modul 3

Implantica
Press release9/24/2025, 6:00 AM

Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3

Implantica
Press release9/17/2025, 6:00 AM

Implanticas RefluxStop® väcker stor entusiasm vid American Foregut Society-mötet, inför det kommande godkännandet av amerikanska FDA

Implantica
Press release9/17/2025, 6:00 AM

Implantica's RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval

Implantica
Regulatory press release9/10/2025, 7:00 PM

Implantica offentliggör utbetalning av aktietilldelningar baserade på det av bolagsstämman godkända aktierelaterade incitamentsprogrammet genom en riktad emission av egna aktier bolaget utan betalning

Implantica
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.